ACTRN12616000961448
Completed
未知
Evaluation of Partnered Pharmacist Medication Charting at Admission: Expansion Project
Alfred Health Pharmacy Department0 sites15,000 target enrollmentJuly 21, 2016
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Hospital admission
- Sponsor
- Alfred Health Pharmacy Department
- Enrollment
- 15000
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients admitted to the General Medical unit for inpatient admission
- •Over 18 years of age
Exclusion Criteria
- •Patients not admitted to the General Medical unit for inpatient admission.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 4
This is a comparative clinical trial of two phakic toric lens in patient with Near-sightedness and cylindrical refractive error.CTRI/2021/12/038930Biotech Healthcare Holdings GmbH
Suspended
Not Applicable
Clinical study to evaluate the safety and efficacy of recMAGE-A3 in patients from which the bladder is removed due to muscle invasive bladder cancer.Muscle invasive bladder cancer, radical cystectomyNL-OMON28470EAU Research Foundation, Arnhem, The Netherlands273
Active, not recruiting
Phase 1
Evaluation of Pamrevlumab for the Treatment of Male Patients Affected by Non-ambulatory Duchenne Muscular Dystrophy and just Treated with Corticosteroidson-ambulatory Duchenne Muscular DystrophyMedDRA version: 20.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2020-000698-26-ATFibroGen, Inc.92
Completed
Not Applicable
A double-blind, randomised, placebo-controlled phase III study of the efficacy of a bivalent Pseudomonas aeruginosa flagella vaccine in patients with cystic fibrosisCystic fibrosisNutritional, Metabolic, EndocrineISRCTN98785888The Society for the fight of Cystic Fibrosis (The Gesellschaft zur Bekämpfung der Mukoviszidose e.V.) (Germany)483
Active, not recruiting
Phase 1
A study to assess the safety, rationale and effect of a new treatment to improve skin function and wound healing in patients with type 2 diabetesType 2 diabetesMedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2017-001351-31-GBniversity of Leeds28